BlackRock Institutional Trust’s Galectin Therapeutics GALT Stock Holding History

BlackRock Institutional Trust’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$41K	Hold	42,034	–	–	﹤0.01%	3723
2016 Q3	$47K	Hold	42,034	–	–	﹤0.01%	3753
2016 Q2	$62K	Hold	42,034	–	–	﹤0.01%	3748
2016 Q1	$60K	Hold	42,034	–	–	﹤0.01%	3776
2015 Q4	$69K	Hold	42,034	–	–	﹤0.01%	3789
2015 Q3	$98K	Hold	42,034	–	–	﹤0.01%	3733
2015 Q2	$115K	Sell	42,034 -115,508	-73%	-$348K	﹤0.01%	3707
2015 Q1	$528K	Sell	157,542 -2,664	-2%	-$9.52K	﹤0.01%	3491
2014 Q4	$556K	Sell	160,206 -11,052	-6%	-$48.8K	﹤0.01%	3479
2014 Q3	$861K	Sell	171,258 -29,847	-15%	-$232K	﹤0.01%	3364
2014 Q2	$2.78M	Buy	201,105 +195,312	+3,372%	+$2.43M	﹤0.01%	3040
2014 Q1	$89K	Buy	+5,793	New	+$82.5K	﹤0.01%	3780

Other funds holding GALT

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

BCA

Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return

CCM

Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BlackRock Institutional Trust's GALT Position: Q4 2016 in Review

BlackRock Institutional Trust held its Galectin Therapeutics (GALT) position steady in Q4 2016 at 42,034 shares worth $41K. The position accounts for ﹤0.01% of the portfolio, ranked #3723.

BlackRock Institutional Trust first reported a position in GALT in Q1 2014 and has held it in 12 quarters since. The position peaked at $2.78M in Q2 2014. 43 funds tracked by Wall St. Rank hold GALT as of Q4 2016.

BlackRock Institutional Trust held 42,034 shares of Galectin Therapeutics worth $41K as of Q4 2016.
BlackRock Institutional Trust left its Galectin Therapeutics share count unchanged in Q4 2016.
Galectin Therapeutics made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #3723 holding.
BlackRock Institutional Trust first reported a position in Galectin Therapeutics in Q1 2014 and has held it in 12 quarters since.
BlackRock Institutional Trust's Galectin Therapeutics position peaked at $2.78M in Q2 2014.
43 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.